Leveraging the company’s designation in Colombia as a National Strategic Project, Khiron Colombia SAS, a subsidiary of Khiron Life Sciences (OTCQX, TSX.V: KHRNF, TSX: KHRN, Frankfurt: A2JMZC), has received authorization to include Mexico as a destination country within its international export quota, with over 700 kg of high-THC extract now available for export to Mexico. In addition, the company has finalized agreements for the manufacture of finished medical cannabis products in Mexico.
Khiron plans to launch its Zerenia clinics across Mexico in 2021, building on the success of its vertically integrated model in Colombia and Peru, & leveraging its education partnership with Tecnologico de Monterrey.
“Our goal is to improve the lives of 1 million patients by 2024, and Mexico remains a very important part of that plan. Thanks to our status as a National Strategic Project, Mexico is now a destination country within our international THC quota, which is expected to accelerate first sales by several months. In addition, we have secured a world class partner that will not only manufacture finished products on our behalf, but also assist with the import and export process. As we continue to advance our proven Zerenia clinic strategy in Mexico, we look forward to delivering our first products to patients in the coming months,” says CEO Alvaro Torres.
Mexico represents a significant market for the Khiron, as a top 15 global economy with a population of nearly 130 million. To date, close to 550 physicians in Latin America have obtained their diploma accrediting completion of Khiron’s medical education program, in partnership with Tecnologico de Monterrey, one of the most prestigious universities in Mexico.